The opposite effect was observed in cells that were deficient for the tuberous sclerosis complex (TSC; an endogenous negative regulator of mTOR activity), in which mTOR is hyperactive: Tsc2 − ...
Cassava's strong liquidity with $128.6 million in cash supports early-stage development, yet long-term funding needs may lead ...
Current treatments, including antiepileptic drugs, mTOR analogs and surgery, are not fully effective, are associated with serious adverse events and/or are invasive. 1 Initially, Cassava will focus on ...
Current treatments, including antiepileptic drugs, mTOR analogs and surgery, are not fully effective, are associated with serious adverse events and/or are invasive. 2 Initially, Cassava will focus on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback